Clinical Trial Update: A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating fasudil, a Rho-kinase inhibitor, for Raynaud's phenomenon (including scleroderma) has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Raynaud Phenomenon
• Systemic Sclerosis

Drugs mentioned

• fasudil (fasudil)

Snippet

Sponsor: Johns Hopkins University | Conditions: Raynaud, Scleroderma | Phase 3 | Status: COMPLETED | Results posted: 2014-11-04